Washington, DC 20549









Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)


June 15, 2017 




GenVec, Inc.

(Exact name of registrant as specified in its charter)




Delaware   000-24469   23-2705690

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


910 Clopper Road

Suite 220N

Gaithersburg, Maryland 20878

(Address of principal executive offices, including zip code)


(240) 632-0740

(Registrant’s telephone number, including area code)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.07. Submission of Matters to a Vote of Security Holders.


On June 15, 2017, GenVec, Inc. (“GenVec”) held a special meeting of shareholders (the “Special Meeting”). GenVec filed a Definitive Proxy Statement for the proposals voted upon at the Special Meeting with the SEC on May 12, 2017, including the proposal to adopt the Agreement and Plan of Merger, dated as of January 24, 2017, among GenVec, Intrexon GV Holding, Inc. (“Merger Sub”) and Intrexon Corporation (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into GenVec (the “Merger”). As described below, the Merger Agreement was adopted, and GenVec anticipates completion of the Merger and the other transactions contemplated by the Merger Agreement on or about June 16, 2017.


As of April 28, 2017, the record date for the Special Meeting, 2,273,632 shares of common stock of GenVec (“GenVec Common Stock”) were issued and outstanding and entitled to vote at the Special Meeting. A quorum of 1,276,211 shares of GenVec Common Stock, or approximately 56.13% of the total shares entitled to vote, were represented in person or by proxy at the Special Meeting. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, with respect to each proposal is set out below:


Proposal No. 1—Adoption of the Merger Agreement.  The Merger Agreement was adopted.


For    Against    Abstain   Broker Non-Votes
1,218,493    50,676    7,042   0


Proposal No. 2—Approval on a non-binding basis of compensation payable to GenVec’s executive officers. The compensation payable was approved.


For    Against    Abstain   Broker Non-Votes
976,460    124,317    175,434   0


No other proposals were submitted at the Special Meeting.







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    GenVec, Inc.

/s/ Douglas J. Swirsky

    Name: Douglas J. Swirsky
    Title: President, Chief Executive Officer and Corporate Secretary


Date: June 15, 2017